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Amopyroquin (Propoquin) in Rheumatoid Arthritis 
By LEE E. BARTHOLOMEW AND IVAN F. DUFF 
A controlled, double-blind trial of amo- 
pyroquin us. placebo has been completed 
in 15 patients with active, classical or 
definite rheumatoid arthritis. 
Improvement in all the parameters 
determined occurred while the patients 
were on amopyroquin. Grip strength, 
sedimentation rate, and Lansbury's in- 
dices showed statistically significant im- 
provement while on amopyroquin. Im- 
provement in the 5o-foot walk and 
A.R.A. functional capacity approached 
statistical significance. 
Amopyroquin was well tolerated, but 
asymptomatic elevation of SGOT oc- 
curred in four patients and appeared to 
be related to the drug. Other tests of 
liver function remained normal. 
Un controlate essayo a duple anonymato 
esseva effectuate con amopyroquina 
contra placebo in un gruppo de 15 pa- 
tientes con active arthritis rheumatoide 
classic o definite. 
Melioration in omne le parametros 
studiate occurreva durante que le pa- 
tientes recipeva amopyroquina. Fortia 
del sasir, sedimentation erythrocytic, e 
le indices de Lansbury indicava statis- 
ticamente significative meliorationes 
durante le curso de amopyroquina. Meli- 
oration in le ambulation de 50 pedes e 
in le capacitate functional secundo le 
A.R.A. approchava un grado de sig- 
nification statistic. 
Amopyroquina esseva ben tolerate, 
sed un elevation asymptomatic de tran- 
saminase glutamic-oxaloacetic del sero 
Occurreva in quatro patientes, apparente- 
mente in relation con le pharmaco. Al- 
tere tests del function hepatic remaneva 
normal. 
ARIOUS SYNTHETIC antimalarial preparations of the 4-amino-quinolone 
group have been used in the treatment of rheumatoid arthritis with en- 
couraging results. A number of well controlled, double-blind studies using 
chloroquine and hydroxychloroquine have shown that both of these drugs 
have anti-rheumatic properties of moderate degree.l-? 
Early reports of the use of amodiaquin (Camoquin) in rheumatoid arthritis 
were also encouraging; but gastrointestinal, neurologic, hepatic, and hemato- 
logic manifestations were serious enough to limit its usefulness.s-10 Similar 
side effects have been reported in the treatment of discoid and systemic lupus 
erythematosus with am~diaquin.l l-~~ Amopyroquin (Propoquin ) is a close 
analogue of amodiaquin (fig. 1). Preliminary studies in animalsl6 and man 
indicated good tolerance, low toxicity, and effective antimalarial properties. 
We, therefore, undertook a preliminary clinical trial to determine the anti- 
rheumatic properties and the toxicity of amopyroquin in patients with rheuma- 
toid arthritis. Classical double-blind, cross-over technics were used to com- 
pare amopyroquin with placebo. 
.- 
From the Rackham Arthritis Research Unit and the Department of Internal Medicine, 
The Rackhm Arthritis Research Unit is supported by (I grant froin the Horuce H .  Rack-. 
Presented in part at the annual meeting of the AmeTZcan R h e u m u h  Association, June 
University of Michigan Medical School, Ann Arbor, Mich. 
ham School of Graduate Studies. 
21 a d  22, 1962 in Chicago, 111. 
356 
~ R ~ I T X S  AND RHEUMATISM, VOL, 6, Na. 4 (AUGUST), 1983 




MATERIALS AND METHODS 
Fifteen adult patients with active, classical or definite rheumatoid arthritis were selected. 
Active disease had been present for at least 1 year, and all patients had at least five clinically 
active joints at the outset of the study. None had ever received antimalarial drugs in the 
past. Systemic steroids had not been used for at least 3 months, although intra-articular 
steroids were used in a few cases during the study. Single joints were injected in three 
patients while on placebo, and in one patient while on amopyroquin. Patients receiving 
maintenance crysotherapy were acceptable if more than 1.5 Gm. had been given, and if 
their disease was stable and active (two cases). Gold was discontinued when the study 
was started. All patients were on salicylates and home physical therapy programs. These 
were continued. At the beginning of the study, patients were instructed in the ad lib. use 
of salicylates. Many, however, tended to continue on their previous dosage despite improve- 
ment. 
The study was of 10 months' duration: 5 months on amopyroquin (Propoquin*), 150 
mg. per day in a single capsule with breakfast, and 5 months on a matching placebo. 
Patients were placed into Group A (amopyroquin first) or Group B (placebo first) by 
random allocation. No one involved in the study was aware of which preparation was 
being given. Patients were seen 14 times during the study; twice before therapy, and a? 
4-week intervals during therapy. An additional visit occured 2 weeks after the start of each 
treatment period in order to note any early side effects. All patients were ambulatory and 
were seen in the Rackham Arthritis Research Unit. As far as possible, patients were seen 
by the same observer on each visit. 
At each visit histories were obtained, and the following items recorded: consistency of 
drug ingestion, average aspirin dosage, other medications, general well-being, and A.R.A. 
functional capacity. Specific questions concerning possible drug toxicity were likewise 
recorded. 
'Propoquin (amopyroquin) and matching placebo were supplied by Dr. P. F. Robert 
de Caries; Parke, Qavis & Co, 
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Table I.-Patient Characteristics at Beginning of Study ______ - 
Group A Group B 
~ ~ _ _ _  
No. patients 8 7 
Males 1 1 
Females 7 6 
Mean age (years) 47 58 
Range 28-62 4 2 6 7  
Duration of disease (years) 3.4 (1.5-7) 5.4 (1-14) 
Positive latex test 5 5 
Rheumatoid nodules 2 4 
I 3 1 
11 3 4 
I11 2 2 
I1 6 4 
2 3 I11 
Stage of R.A. 
Functional capacity 
__. 
Group A: received amopyroquin first 5 months. 
Group B: received placebo first 5 months. 
Hemoglobin, leukocyte count, Westdrgren sedimentation rate, complete urinalysis, blood 
urea nitrogen, and serum glutamic-oxaloacetic transaminase ( SGOT) values were obtained 
at each visit. 
Gxip strength was determined using a small type, English-designed cuff* and inflating 
i o  20 nim. Hg. The three readings of each hand were averaged. The time to walk 50 feet 
a5 fast as possible without running was recorded with a stop-watch. The number and 
location of subcutaneous rheumatoid nodules were noted on each visit. 
Complete physical examinations were performed every 2 months. Weight was recorded 
on each visit. The following were obtained at the first, middle, and final visits: x-rays of 
the hands and wrists, and one other joint ( i f  more active or involved than the hands or 
wrists); latex fixation test to the final dilution; total serum proteins; and serum protein 
paper electrophoresis. 
The following articular indices were recorded: ( 1 )  Tenderness on pressure and/or pain 
on passive motion-a value of one for each joint and half values for doubtful tenderness. 
( 2 )  Joint swelling evaluated on a 0 4  plus scale for each joint. Total numerical values 
were given for both joint tenderness and swelling for each visit. In addition, Lansbury’s 
articular and systemic indices were calculated for each visit.16 The latter were determined 
without values for fatigue. 
Methods of Analysis 
Table 1 shows the composition of the two groups. They were approximately comparable 
in most respects except that the mean age of Group A (receiving amopyroquin first) was 
younger and the mean duration of disease was somewhat shorter. 
Two types of comparisons were made: ( 1 )  A cross-over comparison with each patient 
serving as his own control. Pre-treatment values in Groups A and B were compared with 
those at the end of 5 months, and in turn the 5-month values were compared with those 
obtained at the end of the 10-month period. ( 2 )  Groups A and B were compared for the 
first 5-month period only, with Group A on amopyroquin and Group B on placebo. 
The statistical analyses were performed by Ronald R. Gauch, Department of Clinical 
Investigation, Parke, Davis & Co., Ann Arbor, Mich. The Mann Whitney U Test was used 
for the comparisons between Groups A and B for the first 5-month period. The Wilcoxon 
‘Supplied by Dr. Donald Mainland, New York University Medical Center. 
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Table 2.-Group A (Amopyroquin-Placebo): Mean Values and 
Per Cent Change-Eight Cases 
After 6 Months After 6 Months 
Placebo Amopyropuin 
Pretreatment 
Mean Mean yo Change Bdean %Change' 
Morning stiffness (hours) 
Number of tender joints 
Joint swellingt 
50-foot walk (sec. ) 
Grip strength (mm. Hg) 
Hemoglobin (Gm. % ) 
ESR (mm./hr.) 























+35 + 25 
$11 + 13 
$22 
$6  
+21 + 15 
t 3 5  











+13 + 14 








'4- indicates improvement; - deterioration. 
!Total joint swelling, each joint graded 0-4. 
tlansbury's indices. 
Test was used for the cross-over comparisons. The p values were obtained for each of the 
groups, and values less than 0.05 were considered significant. 
RESULTS 
Of the 15 patients started on the study, one dropped out at the end of 5 
months on placebo. In three patients, the drug was stopped for periods up to 
7 weeks because of SGOT elevation. These patients, as well as one hospitalized 
for 3 weeks for congestive heart failure, are included in the analysis. 
Patients in Group A (table 2) showed mean improvement in all indices 
after 5 months of amopyroquin. This improvement appeared to be maintained 
for the next 5 months on placebo in some indices (morning stiihess, joint 
tenderness, Lansbury's indices, and the 50-foot walk), but not in grip strength 
and sedimentation rate. 
The patients in Group B (table 3)  showed improvement in morning stiff- 
ness and joint tenderness, but no change or deterioration in all other indices 
during the first period on placebo. When switched to amopyroquin, again 
improvement was seen in all indices. 
Statistically, none of the patients showed significant improvement while on 
placebo. In both groups significant improvement was found for some indices 
while on amopyroquin. Grip strength, sedimentation rate and Lansbury's 
systemic index had p values of less than 0.05. The p values for the SO-foot 
walk, functional capacity, and articular index did approach 0.05. 
Table 4 compares the first Smonth period of each group. It is to be noted 
that Group B (placebo) has seven cases-one dropped out at the end of the 
first period. Improvement occurred in all indices in patients receiving amopyro- 
quin, but only Lansbury's articular index was significant ( p = 0.03). However, 
the sedimentation rate and systemic index approached statistical significance. 
In the placebo group, only morning stiffness and total tender joints showed 
improvement. These were not statistically significant. 
Comparing Groups A and B for the first 5-month period, the latex titer fell 
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Table 3.-Group B (Placebo-Amvpyroquin): Mean Values and 
Per Cent Change-Six Cases - 
After 6 Months After 6 Months 
Amopyrwuin Placebo 
Pretreatment 
Mean Mean %Change* Mean %Change* 
Morning stiffness (hours) 
Number of tender joints 
Joint swelling! 
!%-foot walk (see.)  
Grip strength (mm. Hg) 
Hemoglobin (Gm. % ) 
ESR (mm./hr.) 
A.R.A. functional capacity 
Articular index# 
Systemic index1 
2.00 1.46 +27 
31.8 26 f 17 
24 24 0 
11.8 16.8 -51 
123 126 +3 
12.9 12.9 0 
47 52 -11 
2.2 2.2 0 
120 107 +10 













f 4 1  
f 4 5  




f 3 3  
f 3 2  
"+ indicates improvement; - deterioration. 
tTotal joint swelling, each joint graded 0-4. 
tlansbury's indices. 
in four of the five latex positive patients on amopyroquin, and in two of the 
five positive patients on placebo. When switched to amopyroquin, the re- 
maining three patients in the latter group showed a fall in titer. The decrease 
in titer was of two tube dilutions or more in seven cases, and one tube dilution 
in two cases. 
Subcutaneouus nodules disappeared or were decreased in number in three 
patients on amopyroquin, and in one on placebo . 
There was very little change in the gamma globulin values with amopyro- 
quin, but a definite increase in serum albumin occurred. Serum albumin de- 
creased in all except one patient while on placebo. 
No appreciable weight change occurred on amopyroquin. There was a 
mean loss of 1/4 lb. ( -8 to +11 lb.). On placebo, the mean weight change was 
minus 2% Ib. ( -15 to +10 lb.). 
The x-rays revealed very little change during the 10-month period. Erosions 
increased slightly in two patients on placebo, and two on amopyroquin. There 
appeared to be slight improvement in one case while on amopyroquin. 
Toxicity 
Amopyroquin was not stopped in any patient because of untoward symptoms 
or abnormal physical findings. Symptoms suggestive of toxicity were more 
frequent in patients on placebo, particularly anorexia, abdominal distress, 
headaches, and edema. Nausea, vomiting, or diarrhea were not seen while 
on amopyroquin. Skin rash and pruritus likewise were not associated with 
the active preparation. Transient blurred vision was noted in two patients on 
placebo and one on amopyroqdn. These patients and several others had slit 
lamp examinations after the study, and no abnormalities were encountered. 
A transient lowering of the leukocyte count occurred in three patients on 
amopyroquin to levels of 4000-4500 cells/cu. mm. There was essentially no 
change in values far blood urea nitrogen w complete urinalyses. 
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Table 4.-compwk~n of Mean Values and Per Cent Change of Eight cb.se8 
Started on Amqyroquin with Seven Caw38 Started on Plucebo 
After 5 Months 
Pretreatment Pretreatment 
After 6 Months 
Amopymuin Placebo 
Mean Mean 0/0Change* Mean Mean % Change' 
Morning stiffness 
Number of tender 
( hours ) 2.72 1.76 +35 2.12 1.68 4-21 
joints 28 21 +25 31.6 28 $11 




( sec. ) 11.6 10.1 $13 12.6 17.7 -41 
(mm. Hg ) 140 171 +22 122 123 0 
(Gm. % 1 12.2 13.0 $6 12.9 12.8 -1 
ESR (mm./hr.) 43 34 $21 53 57 -7 
capacity 2.1 1.8 +14 2.2 2.2 0 
Articular index+ 105 68 $35 117 115 +2 
Systemic index4 76 58 $24 71 67 +5 
A.R.A. functional 
*+ indicates improvement; - deterioration. 
tTotal joint swelling, each joint graded 0-4. 
t Lansbur y 's indices. 
In four patients definite elevation of SGOT occurred while taking amo- 
pyroquin. The highest values for each patient ranged from 106 to 440 units 
(normal 15-40 units). One patient was a 72-year-old lady who developed mild 
congestive heart failure. Left bundle branch was found on her electrocardio- 
gram. She was continued on amopyroquin; and the SGOT values fell from 106 
units at 3 months of therapy to 77 units at the end of 5 months of therapy. 
Two weeks after switching to placebo the SGOT became normal. 
The other three patients were asymptomatic. Elevated SGOT levels were 
first noted after 1 to 2 months of treatment. The drug was stopped in each 
instance for 4 to 7 weeks, at which time the SGOT had significantly dropped. 
In each case it was restarted. In one patient the values gradually fell to nor- 
mal while continuing amopyroquin. In the other two cases the values again 
became elevated, but not as high as originally. 
Serum bilirubin, bromosulfalein excretion, and alkaline phosphatase tests 
remained normal. Two patients had positive cephalin flocculation tests, but 
pretreatment values were not available. None of the patients developed hepato- 
splenomegaly or liver tenderness. 
DISCUSSION 
The purpose of this study was to determine whether or not amopyroquin 
has anti-rheumatic properties, and how toxic the drug might be in patients 
with rheumatoid arthritis. Patients with both mild and early, and severe 
and late rheumatoid arthritis were selected. The cross-over, double-blind 
technic seemed the most suitable rnethod for study, Treating the data in 
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a cross-over trial is always subject to some bias, since the preparation given 
initially has a better chance of causing improvement than the preparation given 
during the second half of the trial. However, three patients who developed 
elevated SGOT levels were taken off amopyroquin for periods of 4 to 7 weeks. 
They are included in the evaluation, and this would tend to decrease the ap- 
parent effectiveness of the drug. Nevertheless, amopyroquin appears to have 
definite, but moderate anti-rheumatic properties. 
The results, as shown, compare only the initial and final values for each 
period. The various indices were determined six times for each .!&month period. 
When improvement occurred with amopyroquin, it was gradual and usually 
was seen first at the end of 4 weeks. A definite carry-over effect occurred in 
Group A (amopyroquin first) which lasted 2 to 4 months or longer during 
the placebo period. 
Amopyroquin was very well tolerated in this group of patients. This is 
somewhat surprising since amodiaquin caused side effects in a high proportion 
of patients. The significance of the elevated SGOT levels is yet to be deter- 
mined. Presumably, this represents liver transaminase, though there was no 
other evidence of liver involvement. We have not eliminated other sources of 
transaminase release. The presence of amopyroquin itself in serum does not 
interfere with the colorimetric method17 of determining SGOT as used in our 
hospital.l* Bepler et a1.8 reported serum transaminase elevation up to 100 
units in four patients treated with amodiaquin. 
The dosage of amopyroquin (150 mg./day) was arbitrarily chosen on the 
basis of results in preclinical and early clinical trials. Perhaps higher or lower 
doses could be used to advantage. 
This study again demonstrates the sensitivity of Lansbury’s indices. In addi- 
tion to Lansbury’s indices, sedimentation rate and grip strength individually 
were good indicators of disease activity. 
SUMMARY 
A controlled, double-blind trial of amopyroquin 0s. placebo has been com- 
pleted in a group of 15 patients with classical or definite rheumatoid arthritis. 
Improvement occurred while on amopyroquin in the various indices re- 
corded, wfith statistical significance noted in Lansbury’s indices, grip strength 
and sedimentation rate. 
Amopyroquin was well tolerated, but elevation of SGOT occurred in four 
of the patients, 
.*. 
REFERENCES 
1. Cohen, A. S., and Calkins, E.: A con- 
trolled study of chloroquine as an 
anti-rheumatic agent. Arth. & Rheu- 
mat. 1:297, 1958. 
2. Freedman, A., and Steinberg, V. L.: 
Chloroquine in rheumatoid arthri- 
tis; a double blind fold. trial pf 
treatment for one year. Ann. Rhiiii 
mat. Dis. 19:243, 1960. 
3. Popert, A. J., Meijers, K. A. E., Sharp, 
J., and Bier, F.: Chloroquine diphos- 
phate in rheumatoid arthritis. Ann. 
Rheumat. Dis. 20:18, 1961. 
4. Freedman, A.: Chloroquine and rheu- 
matoid arthritis: a short-term con- 
trolled trial. Ann. Rheumat. Dis. 15: 
251, 1956. 
5. Mainland, D., and Sutcliffe, M. I.: Hy- 
droxychloroquine siilfate in rheuma- 
toid arthritis, a six month, double- 
AMOPYROQUIN IN RHEUMATOID ARTHRITIS 363 
blind trial. Bull. Rheumat. Dis. 13: 
287, 1962. 
6. Scull, E.: Chloroquine and hydroxy- 
chloroquine therapy in rheumatoid 
arthritis. Arth. & Rheumat. 5:30, 
1962. 
7. Hamilton, E. B. D., and Scott, J. T.: 
Hydroxychloroquine sulfate (“Pla- 
quenil”) in treatment of rheumatoid 
arthritis. Arth. & Rheumat. 5:502, 
1962. 
8. Bepler, C. R., Baier, H. N. McCracken, 
S., Rentschler, C. L., Rogers, F. B., 
and Lansbury, J.: A 15 month con- 
trolled study of the effects of amodia- 
quin (Camoquin) in rheumatoid ar- 
thritis. Arth. & Rheumat. 2:403, 
1959. 
8. Pomeroy, H., Warren, C., Mills, D., 
and Clark, G. M.: The effect of 
amodiaquin (Camoquin) on the 
course of rheumatoid arthritis. Arth. 
& Rheumat. 2:396, 1959. 
10. Kersley, G. D.: Amodiaquine and hy- 
droxychloroquine in rheum3toid ar- 
thritis. Lancet 2:886, 1959. 
11. Leeper, R. W., and Allende, M. F.: 
Antimalarials in the treatment of dis- 
coid lupus erythematosus. Special 
reference to amodiaquin (Camoquin). 
A. M. A. Arch. Dermat. 73:50, 1956. 
12. Bliel, D. C.: Unusual toxic manifesta- 
tions to amodiaquin (Camoquin). 
A. M. A. Arch. Dermat. 77:106, 1956. 
13. Glick, L.: Fatal agranulocytosis dur- 
ing treatment with amodiaquin. Brit. 
M. J. 1:932, 1957. 
14. Pappenfort, R. B., and Lockwood, J. 
H.: Amodiaquin (Camoquin) in the 
treatment of chronic discoid lupus 
erythematosus. A.M.A. Arch. Dermat. 
74:384, 1956. 
15. Thompson, P. E., Weston, K., Glazko, 
A. J., Fisken, R. A., Reutner, T. 
F., Bayles, A., and Weston, J. K.: 
Laboratory studies on amopyroquin 
(Propoquin), an antimalarial com- 
pound. Antibiotics & Chemother. 8: 
450, 1958. 
16. Lansbury, J.: Report of a three-year 
study on the systemic and articular 
indexes in rheumatoid arthritis. Arth. 
& Rheumat. 1:505, 1958. 
17. Reitman, S., and Frankel, S.: Colori- 
metric method for the determina- 
tion of serum transaminase activity. 
Am. J. Cin. Path. 28:56, 1957. 
18. Unpublished observations. 
Lee E .  Bartholomew, M.D., Assistant Professor of Internull 
Medicine, University of Miohigan Medical Center, Ann Arbor, 
Mich. 
Ivan F .  Duf,  M.D., F.A.C.P., Professor of Internal Medicine 
in churge of Rackham Arthritis Research Unit, Unimsity of 
Michigan Medical Center, Ann Arbor, Mich. 
